Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).

被引：0
|
作者：
Apolo, Andrea Borghese
Lee, Young H.
Cecchi, Fabiola
Agarwal, Piyush K.
Parnes, Howard L.
Khadar, Kattie
Summerell, Amelia
Gulley, James L.
Compton, Kathryn
Figg, William Douglas
Dahut, William L.
Bottaro, Donald P.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[4] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
[5] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4543
引用
收藏
页数：1
相关论文
共 50 条
  • [41] MOLECULAR PROFILE AND ANTI-TUMOR ACTIVITY IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) IN A PHASE 1 STUDY OF CABOZANTINIB (XL184) IN JAPAN
    Nokihara, H.
    Yamamoto, N.
    Nakamichi, S.
    Wakui, H.
    Yamada, Y.
    Frye, J.
    Decillis, A.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 174 - 174
  • [42] Phase 2 study of XL184 in a cohort of ovarian cancer patients (pts) with measurable soft tissue disease
    Vergote, I.
    Sella, A.
    Bedell, C.
    Ramondetta, L.
    Shapiro, G. I.
    Balic, K.
    Prokopczuk, E.
    Sauer, L.
    Tseng, L.
    Berger, R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 129 - 129
  • [43] Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.
    Gordon, M. S.
    Vogelzang, N. J.
    Schoffski, P.
    Daud, A.
    Spira, A. I.
    O'Keeffe, B. A.
    Rafferty, T.
    Lee, Y.
    Berger, R.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
    Coyne, Geraldine O'Sullivan
    Kummar, Shivaani
    Hu, James
    Ganjoo, Kristen
    Chow, Warren A.
    Do, Khanh T.
    Zlott, Jennifer
    Bruns, Ashley
    Rubinstein, Lawrence
    Foster, Jared C.
    Juwara, Lamin
    Meehan, Robert
    Piekarz, Richard
    Streicher, Howard
    Sharon, Elad
    Takebe, Naoko
    Voth, Andrea Regier
    Bottaro, Donald
    Costello, Rene
    Wright, John J.
    Doroshow, James H.
    Chen, Alice P.
    CLINICAL CANCER RESEARCH, 2022, 28 (02) : 279 - 288
  • [45] Antitumor activity observed in a phase I drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC)
    Choueiri, T. K.
    Pal, S. K.
    Cabanillas, M. E.
    Ramies, D. A.
    Tseng, L.
    Holland, J. S.
    Morrissey, S.
    Dutcher, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial
    Shih, Chie-Schin
    Blakeley, Jaishri
    Clapp, D. Wade
    Armstrong, Amy E.
    Wolters, Pam
    Dombi, Eva
    Cutter, Gary
    Ullrich, Nicole J.
    Allen, Jeffrey
    Packer, Roger
    Goldman, Stewart
    Gutmann, David H.
    Plotkin, Scott
    Rosser, Tena
    Robertson, Kent
    Widemann, Brigitte
    Rhodes, Steven
    Angus, Steven
    Johnson, Gary
    Korf, Bruce
    Fisher, Michael J.
    CANCER RESEARCH, 2019, 79 (13)
  • [47] Anti-tumor activity observed in an ongoing phase 1 drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma
    Choueiri, T. K.
    Pal, S. K.
    McDermott, D. M.
    Ramies, D. A.
    Morrissey, S.
    Lee, Y.
    Miles, D.
    Holland, J. S.
    Dutcher, J. P.
    BJU INTERNATIONAL, 2012, 109 : 4 - 4
  • [48] Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Yasenchak, C.
    Nackaerts, K.
    Awada, A.
    Gadgeel, S. M.
    Hellerstedt, B.
    Perry, M. C.
    Richards, D.
    Yang, C. H.
    Scheffold, C.
    Lara, P. N., Jr.
    EJC SUPPLEMENTS, 2010, 8 (07): : 126 - 126
  • [49] NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY
    Shih, Chie-Schin
    Blakely, Jaishri
    Clapp, Wade
    Wolters, Pam
    Dombi, Eva
    Cutter, Gary
    Ullrich, Nichole
    Allen, Jeffrey
    Packer, Roger
    Goldman, Stewart
    Gutmann, David
    Plotkin, Scott
    Rosser, Tena
    Robertson, Kent
    Widemann, Brigitte
    Korf, Bruce
    Fisher, Michael
    NEURO-ONCOLOGY, 2018, 20 : 142 - 142
  • [50] Phase 2 study of XL184 in a cohort of patients (pts) with castration resistant prostate cancer (CRPC) and measurable soft tissue disease
    Smith, D. C.
    Spira, A.
    De Greve, J.
    Hart, L.
    Holbrechts, S.
    Lin, C. C.
    Hussain, M.
    Herrick, S.
    Houggy, K.
    Vogelzang, N.
    EJC SUPPLEMENTS, 2010, 8 (07): : 129 - 129
12345